盐酸哌罗匹隆治疗精神分裂症的 临床疗效观察

目的 验证盐酸哌罗匹隆治疗精神分裂症的疗效及安全性.方法 将50例精神分裂症患者随机分配到盐酸哌罗匹隆组25例和阿立哌唑组25例进行为期8周的随机双盲对照研究,采用阳性和阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效,用副反应记录表评价副反应.结果 治疗8周后两组患者PANSS总分及各因子分,均较...     

哌罗匹隆与喹硫平治疗首发精神分裂症的临床研究

目的比较哌罗匹隆与喹硫平治疗首发精神分裂症的疗效及安全性。方法将64例首发精神分裂症患者随机分为哌罗匹隆组(研究组)32例,喹硫平组(对照组)32例,分别给予哌罗匹隆和喹硫平治疗,疗程6周。采用阳性与阴性症状量表(PANSS)评定疗效,治疗时出现的症状量表(TESS)评定不良反应。结果治疗6周后两组PANSS评分较治疗前均有显著下降。哌罗匹隆组显效率为65.6%,有效率为78.1%;喹硫平组显效率为62.5%,有效率为75%,两组间疗效差异无统计学意义(P>0.05),两组间TESS评分差异亦无统计学意义。结论哌罗匹隆治疗首发精神分裂症的疗效及安全性与喹硫平相当。     

哌罗匹隆联合艾司西酞普兰治疗阴性症状为主的精神分裂症临床观察

目的探讨哌罗匹隆联合艾司西酞普兰治疗以阴性症状为主的精神分裂症临床疗效。方法选取以阴性症状为主的精神分裂症患者60例,随机分为研究组(n=30)与对照组(n=30)。研究组给予哌罗匹隆联合艾司西酞普兰治疗,对照组给予哌罗匹隆治疗。观察8周,于治疗前、治疗后2、4、8周末采用PANSS量表、阴性症状量表(SANS)、不良反应量表(TESS)评定疗效及不良反应。结果研究组总有效率76.7%,对照组为53.3%比较,差异有统计学意义(P0.05)。研究组在治疗2周末SANS量表评分下降较显著(P0.01)。与治疗前相比,治疗8周末2组PANSS量表评分均显著下降(P0.05),TESS评分无明显差异(P0.05)。结论哌罗匹隆联合艾司西酞普兰治疗以阴性症状为主的精神分裂症起效快,疗效好。     

帕利哌酮缓释片与盐酸哌罗匹隆片治疗精神分裂症患者临床疗效观察

目的 比较帕利哌酮缓释片与盐酸哌罗匹隆片治疗精神分裂症患者的疗效和安全性.方法 将70例精神分裂症患者随机分为帕利哌酮组和哌罗匹隆组.两组患者入组治疗前均停用抗精神病药至少2周.哌罗匹隆组患者给予盐酸哌罗匹隆片口服,初始剂量8毫克,2周后逐渐增加至12-48毫克;帕利哌酮组给予帕利哌酮缓释片,初始剂量3毫克,2周后剂量...     

哌罗匹隆治疗精神分裂症患者的疗效以及对内分泌的影响

目的:探讨哌罗匹隆治疗精神分裂症的疗效及对内分泌的影响. 方法:64例精神分裂症患者分为哌罗匹隆组和利培酮组各32例,分别予哌罗匹隆和利培酮治疗6周.采用阳性和阴性症状量表(PANSS)及治疗中出现的症状量表(TESS)在治疗前后评定疗效及不良反应,同时测定血清催乳素(PRL)及促甲状腺激素(TSH)、三碘甲状腺原氨酸(T3)、游离三碘甲状腺原氨酸(FT3)、甲状腺素(T4)、游离甲状腺素(FT4)水平. 结果:哌罗匹隆组总有效率78.13％,利培酮组81.25％(x2=0.097,P＞0.05).两组治疗后PANSS评分均较治疗前显著下降(P＜0.05或P＜0.01)；两组TESS评分治疗1周和6周差异均无统计学意义(t=-1.84,-1.35;P均＞0.05).哌罗匹隆组PRL(t=-1.26)及各项甲状腺激素(t=0.97～1.88)水平治疗前后差异无统计学意义(P均＞0.05). 结论:哌罗匹隆治疗精神分裂症疗效与利培酮相当,但对PRL和甲状腺激素的影响较小.     

哌罗匹隆及利培酮治疗首次发病的老年精神分裂症对照研究

目的:探讨哌罗匹隆治疗老年期首发精神分裂症的疗效及其对体质量、糖脂代谢的影响。方法:72例老年期首发精神分裂症患者随机分为哌罗匹隆组和利培酮组并予以相应的药物治疗8周。治疗前后进行阳性和阴性症状量表(PANSS)、临床总体印象量表(CGI-SI)及治疗中出现的症状量表(TESS)评定,以及体质量、血糖、血脂测定。结果:治疗后哌罗匹隆组总有效率(83.33%)与利培酮组(80.56%)差异无统计学意义(χ2=0.094,P0.05);哌罗匹隆组低密度脂蛋白水平较治疗前明显增加(P0.05);利培酮组体质量、空腹血糖、餐后2 h血糖、血三酰甘油、总胆固醇及低密度脂蛋白水平较治疗前明显增加,高密度脂蛋白水平明显降低(P0.05或P0.01);两组TESS评分差异无统计学意义。结论:哌罗匹隆治疗老年期首发精神分裂症的疗效与利培酮相当,对体质量、糖脂代谢影响较小。     

齐拉西酮与舒必利治疗精神分裂症的对照分析

目的 比较齐拉西酮与舒必利治疗精神分裂症的临床疗效及安全性,为精神分裂症的治疗积累经验.方法 把80例精神分裂症患者随机分组治疗,研究组予齐拉西酮治疗,共完成40例,平均剂量为(142.8±21.3)mg/d,对照组予舒必利治疗,共完成38例,平均剂量(622.3±152.5)mg/d,观察8周.2组于治疗前及治疗第1、2、4、8周末分别评定阳性与阴性症状量表(PANSS)及副反应量表(TESS).结果 研究组第1周末和第2周末的PANSS总分减分率极显著高于对照组(P<0.01),研究组第4周末和第8周末的PANSS总分减分率与对照组差异无统计学意义(P>0.05),第8周末两组疗效相当(P>0.05).研究组的不良反应总发生率(20.0%)显著低于对照组(42.1%)(P<0.05).结论 齐拉西酮治疗精神分裂症的疗效与舒必利相当,但起效较早且不良反应较少.     

盐酸哌罗匹隆治疗首发精神分裂症患者的效果及不良反应

目的探讨首发精神分裂症患者接受盐酸哌罗匹隆治疗的临床效果及不良反应。方法将2019年1月～2020年7月接受利培酮治疗的35例首发精神分裂症患者作为对照组,将同期接受盐酸哌罗匹隆治疗的35例首发精神分裂症患者作为观察组,对组间阳性和阴性症状量表(PANSS)评分、社会功能、血清泌乳素(PRL)、临床治疗效果、不良反应展开分析。结果 (1)组间PANSS评分在治疗前无明显差异;治疗8周后,两组PANSS评分均降低,且组间PANSS评分无明显差异(P0.05);(2)组间社会功能评分在治疗前无明显差异;治疗8周后,观察组社会性退缩、职业和工作、兴趣关心评分低于对照组(P0.05);(3)组间PRL在治疗前无明显差异;观察组治疗第3周、第8周时的PRL水平均低于对照组(P0.05);(4)治疗8周后,观察组3例无效(8.57%),对照组5例无效(14.29%),两组疗效相当(P0.05);(5)观察组的不良反应为5.71%,低于对照组的22.86%(P0.05)。结论盐酸哌罗匹隆与利培酮治疗首发精神分裂症患者的疗效相当,均能改善患者阳性和阴性症状,但是盐酸哌罗匹隆更好的改善患者的社会功能,不良反应更少,对PRL影响更小。     

阿立哌唑与利培酮治疗精神分裂症对照研究

目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效及不良反应。方法:将60例精神分裂症患者随机平分为两组。阿立哌唑剂量为10~30mg/d,利培酮为2~6mg/d。疗程8周。采用阳性与阴性症状量表(PANSS)评定疗效,采用副反应量表(TESS)评定不良反应。结果:阿立哌唑组有效率为66.7%,利培酮组为70·0%,两组差异无显著性。阿立哌唑组的不良反应较利培酮组少,其中震颤、静坐不能、肌强直等发生率显著少于利培酮组。结论:阿立哌唑与利培酮治疗精神分裂症的疗效相当,某些不良反应较利培酮组轻而少。     

哌罗匹隆与奥氮平治疗脑血管病伴发精神行为症状对照研究

目的比较哌罗匹隆与奥氮平治疗脑血管病伴发精神行为症状的疗效及不良反应。方法把符合研究条件的54例患者随机分为哌罗匹隆组和奥氮平组,分别给予哌罗匹隆与奥氮平治疗,采用阳性和阴性症状量表(PANSS)、日常生活能力量表(ADL)和副反应量表(TESS)评定疗效和不良反应。研究共观察6周,治疗前和治疗后的2、4、6周末各评定1次。结果研究中脱落5例。2组治疗后PANSS和ADL评分均明显下降,PANSS评分:2周末、4周后与治疗前比较,差异均有统计学意义(P0.05,P0.01),组间同期比较无显著差别(P0.05)。ADL评分:4周末、6周末与治疗前比较,差异均有统计学意义(P0.05,P0.01),6周末组间比较有显著差别(P0.05)。哌罗匹隆组显效率44.00%,有效率76.00%;奥氮平组显效率41.67%,有效率70.83%,差异无统计学意义(χ~2=0.03和0.17,P0.05)。2组总不良反应发生率无明显差异(χ~2=0.34,P0.05)。结论哌罗匹隆治疗脑血管病伴发的精神行为症状疗效显著,能明显提高患者的日常生活能力,与奥氮平疗效相当,二者不良反应无明显差异,但奥氮平的镇静作用不利于患者生活质量提高。     

Influence of abciximab on the adhesion of platelets on a shielded plasma gradient prepared on polyethylene

INTRODUCTION: Thrombotic effects of biomaterial implants are mediated merely through activation of the platelet glycoprotein IIb-IIIa (GpIIb-IIIa) receptor. Consequently, platelet GpIIb-IIIa receptor inhibitors are successfully used during stent implantation procedures to prevent thrombosis. However, currently a new generation of stents contains surface coating, which changes the surface to more hydrophobic or hydrophilic. This change markedly affects the interaction of platelets and may influence the efficiency of GpIIb-IIIa inhibitors. MATERIALS AND METHODS: To study the influence of the wettability of biomaterials on the effectiveness of abciximab, 5-cm polyethylene gradients with contact angles of 100 degrees to 40 degrees were made by means of glow discharge. Fresh whole blood with or without abciximab was recirculated over this gradient. RESULTS: Inhibition of platelet adhesion by abciximab was maximal, but not complete, on the hydrophobic and moderate hydrophobic part of the gradient, with contact angles of 55 degrees to 90 degrees. Percentage inhibition by abciximab was maximal around 60 degrees. CONCLUSIONS: Intermediate hydrophobicity of currently applied stent materials, such as stainless steel, seems optimal in combination with abciximab. However, on hydrophobic and particularly on hydrophilic materials, abciximab is less effective.     

Laser therapy on points of acupuncture on nerve repair

正Paresthesia is the name given to a temporary or permanent sensory loss caused by several surgical procedures that affected the peripheral sensory nerve.In dentistry,common iatrogenic procedures that can lead to sensory loss include third molar removal,blocking of the inferior alveolar nerve     

Effects of lorazepam on rate of forgetting,on retrieval from semantic memory and on manual dexterity

Using a double-blind procedure, 16 out of 32 volunteer subjects (students) each took 2.5 mg of lorazepam (Ativan) orally and the remainder took a placebo. To overcome the problem of wide variation in individual tolerance to the drug, impairment on a task unrelated to memory (a manual dexterity task) was used to divide drug subjects into a group appreciably affected by the drug. subgroup 1, and a group minimally affected, subgroup 2. Only subgroup 1 showed consistent impairment of episodic memory. Both subgroups showed some impairment in a semantic memory task (generation of words from a specified category), but this was confined to the rate at which the task was carried out. The main aim of the experiment was to examine the effect of lorazepam on the rate of forgetting of word lists when drug and control subjects' initial recall levels were equalized. There was no evidence that the drug affected rate of forgetting: this suggests that it does not affect retention. There was also no evidence that it affected retrieval, since there was no impairment in the recall of material presented before administration of the drug. Hence its locus of action is attributed to input, specifically to impaired encoding of contextual information.     

不同病房模式对精神分裂症病情影响的研究

目的探讨不同病房模式对首发精神分裂症患者病情的影响及康复情况。方法开放式病房的患者为研究组68例,同时选择住封闭式病房患者为对照组130例,对两组患者的临床资料进行比较分析。结果对照组患者入院时焦虑抑郁及敌对猜疑出现明显变化（P＜0.05）;研究组患者在第1周时焦虑抑郁已经开始改善,第2周时病情、阳性症状、一般精神病理、敌对猜疑、激活性也出现明显变化（P＜0.05）;第4周时研究组病情及各因子、认知功能及自知力显著改善,与对照组比较存在统计学差异（P＜0.05）。结论开放式病房模式可以减少患者的负性影响,更快改善患者的认知功能,有利于患者自知力的恢复,使患者的病情达到更全面的康复。     

Efficacy of milnacipran on poststroke depression on inpatient rehabilitation

Post-stroke depression (PSD) has a negative impact on rehabilitation following stroke. No satisfactory antidepressant treatment for PSD has yet been developed. The present study examined the effect of milnacipran, a serotonin and norepinephrine reuptake inhibitor, on PSD patients. Eleven PSD patients taking milnacipran in a rehabilitation hospital were compared to age-matched, sex-matched, and severity of depression at admission-matched PSD patients hospitalized during 2001 who did not take any antidepressant as historical control. Severity of depression was measured using self-rating depression scale for depression (SDS) assessed at admission and discharge after 3 months inpatient rehabilitation. Activities of daily living (ADL) and quality of life (QOL) were measured, respectively, by the functional independence measure (FIM) and a self-completed questionnaire for QOL (QUIK) as outcomes of rehabilitation. For the SDS score, the group taking milnacipran showed significant improvement compared to the control group in our study. FIM was improved in both groups. In the end QUIK did not change significantly in either group. We found no major side-effects of milnacipran among the patients. These results suggest that milnacipran is a safe and effective treatment for PSD for inpatients undergoing rehabilitation.     

Certain predictions on the effectiveness of l-DOPA on parkinsonism

Summary Sixty nine patients with Parkinson's disease were treated with L-DOPA for more than a year. L-DOPA produced remarkable improvement in akinetic patients, moderate improvement in rigidity and slight improvement in tremor. The degree of improvement in akinesia, rigidity and tremor tended to be reversely related to the severity of the disease. Rigidity and akinesia improved better in young patients, but there was no correlation between age and the response of tremor to the treatment. Except for rigidity there was no correlation between the improvement and the duration of the disease.

---

Zusammenfassung 69 Parkinsonpatienten wurden während mehr als 1 Jahr mit L-DOPA behandelt. Es wurde dadurch bei akinetischen Patienten eine beachtliche, bei Patienten mit Rigor eine mäßige und bei Patienten mit Tremor eine geringfügige Besserung erreicht. Das Ausmaß der Besserung war in allen drei Formen um so geringer, je ausgeprägter die Symptome bei Behandlungsbeginn waren. Rigor und Akinesie sprachen bei jungen Patienten besser auf die Therapie an, aber es bestand keine Korrelation zwischen dem Alter der Patienten und der Beeinflußbarkeit des Tremors durch die L-DOPA-Therapie. Außer für den Rigor bestand keine Korrelation zwischen dem Ausmaß der Besserung und der Dauer der Erkrankung vor Behandlungsbeginn.